Cellular Origins acquires ACTIA Platform to enhance automated cell therapy production
Cellular Origins, a TTP company specialising in cell and gene therapy (CGT) manufacturing solutions, has announced the acquisition of the Autologous Cell Therapy Industrial Automation (ACTIA) Platform intellectual property. The acquisition is set to augment the company’s existing Constellation™ platform, which was launched in May 2023.